ArticlePLoS pathogens2025
Paramyxovirus matrix protein redirects METTL3 for dual regulation of viral replication and immune evasion.
Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
N6-methyladenosine (m6A) epitranscriptomic modifications play crucial roles in regulating both host and viral gene expression. Here, we revealed a novel mechanism by which paramyxoviruses exploit host m6A machinery to simultaneously enhance viral replication and suppress host immunity. Our results demonstrated that the viral matrix protein (M) of bovine parainfluenza virus type 3 (BPIV3) binds to the methyltransferase domain of METTL3 in the nucleus and facilitates its translocation to the cytoplasm through an exportin-1-dependent pathway. This mechanism is conserved across multiple paramyxoviruses, including human parainfluenza virus type 3, Sendai virus, Nipah virus, and measles virus, suggesting an evolutionarily conserved viral strategy. The relocated METTL3 catalyzes m6A modification at specific sites within viral nucleocapsid protein (N) mRNA, significantly enhancing its stability and protein expression. Using reverse genetics, we generated recombinant viruses harbouring mutations at these m6A acceptor sites, which exhibited markedly attenuated viral replication, confirming the critical role of these epitranscriptomic marks in the viral life cycle. Rescue experiments demonstrated that the expression of exogenous N protein partially restored the viral titer and concomitant genome/antigenome synthesis in m6A site mutant, indicating that reduced N protein abundance represents a key mechanism underlying impaired viral replication. Furthermore, M protein-mediated depletion of nuclear METTL3 significantly reduces m6A modification of host IFN-β mRNA, resulting in diminished interferon expression and compromised antiviral responses. Supporting this mechanism, infection with viruses bearing nuclear export signal mutations that prevent METTL3 cytoplasmic translocation, maintained IFN-β mRNA m6A modification and resulted in significantly elevated IFN-β expression. These findings provide direct mechanistic evidence that paramyxoviruses utilize M-driven METTL3 relocalization as a sophisticated immune evasion strategy. Our study illuminates how paramyxoviruses strategically manipulate epitranscriptomic regulation to create an environment conducive to viral propagation, thereby advancing our understanding of virus-host interactions and identifying potential targets for antiviral therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.